FBFelipe Matias Berg

Felipe Matias Berg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Felipe Matias Berg has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits

    by Felipe M. Berg, Eric C. Abenojar, Pinunta Nittayacharn, Nathan K. Hoggard, Sidhartha Tavri, Jing Wang, Felipe Matsunaga, Michaela B. Cooley, Dana Wegierak, Xinning Wang, et al.

  • Formulation and activation of lipid-shelled nanobubble ultrasound contrast agents

    by Michaela B. Cooley, Theresa Kosmides, Pinunta Nittayacharn, Felipe M. Berg, Dana Wegierak, Dorian Durig, Agata A. Exner


  • Open Access

    New Frontiers in Contrast-Enhanced Ultrasound for Cancer Imaging

    by Felipe Matias Berg, Michaela Briana Cooley, Theresa Kosmides, Laura E. Chen, Ronaldo Hueb Baroni, Agata A. Exner

    Nanobubbles (NBs) are increasingly recognized as the next generation of ultrasound contrast agents that can provide alternate avenues for the advancement of cancer imaging and therapy. Compared to currently clinically viable microbubbles that are limited to the vasculature because of their size, nanobubbles with diameters ranging from 200 to 500 nm can potentially target the perivascular and possibly extravascular compartments. Their polymeric, lipid, or hybrid shells can be engineered to tune stability, increase circulation time, and support surface functionalization with ligands to facilitate receptor-directed binding. Preclinical studies show that NBs can extend ultrasound imaging windows, improve sensitivity, and increase tumor-to-background contrast across different types of cancers. NBs can also be formulated with secondary reporters that allow their combination with other imaging modalities, such as optical (photoacoustic and fluorescence) and magnetic resonance imaging. However, several challenges need to be overcome to allow the clinical translation of NBs, such as acoustic optimization and standardization, formulation and manufacturing reproducibility, and comprehensive safety characterization. Addressing these barriers will be essential to establishing NBs as clinically viable agents. Here, we summarize recent advances in NB design and functionalization, review key preclinical oncology applications, and discuss translational priorities to support their integration into precision oncology clinical workflows.


  • Open Access

    Pathology of a Canine Model of Localized Prostate Carcinoma

    by Nathan K. Hoggard, Felipe M. Berg, Marlon R. Szczepaniak, Xinning Wang, Noriko Kantake, Gopalakrishnan Ramamurthy, Li Gong, Eric T. Hostnik, Krishan Kumar, Arijit Ghosh, et al.

    Background: Dogs spontaneously develop prostate carcinoma (PC) and share prostate gland anatomy, physiology, and size to men. Over the last 15 years, we have developed and refined a canine model of focal PC to evaluate therapeutic‐diagnostic (theranostic) interventions. A comprehensive description of the pathology and synthesis of the various studies has not been performed. The goal of this manuscript was to describe the canine model tumor pathology within the framework of its methodological development to help guide future translational PC research. Methods: In published and unpublished studies, we previously inoculated prostate glands of immunosuppressed, intact beagle dogs ( n = 56) with a canine PC cell line (Ace‐1) transduced with human or canine genes for targeted theranostics. Gross tumor assessment and histology were performed in all cases. Molecular tumor and microenvironmental pathology was investigated using digital image analysis, immunohistochemistry, laser‐capture microdissection, and quantitative real‐time PCR. Results: The model reliably (85.7% engraftment rate) formed prostatic tumors resembling intermediate and high‐grade localized PC, with poorly differentiated morphology, stromal invasion, and peripheral growth. Soft tissue metastasis occurred in 13/48 (27.1%) dogs. Most dogs formed multifocal prostatic tumors with occasional tumors outside the prostate gland. Tumor location influenced growth behavior and the microenvironment. Allografts were histologically classified as intraglandular intraprostatic, invasive intraprostatic, capsular, or extraprostatic. Compared to intraprostatic tumors, capsular/extraprostatic tumors had increased proliferation (Ki‐67 index), epithelial‐to‐mesenchymal transition, and microenvironmental alterations that included increased collagenous stroma, fibroplasia, and reduced immune cell infiltration. Conclusions: The canine model of PC captured important pathologic features of men undergoing curative‐intent therapy alongside model‐ and species‐specific characteristics of interest to researchers. Beyond defining pathology, the results highlighted applications of the canine model in studying the tumor microenvironment and advancing preclinical, anti‐cancer strategies in a large animal species.

  • Open Access

    Preclinical Evaluation of PSMA-Targeted Ultrasound Contrast Agents in an Orthotopic Model of Prostate Cancer in Rabbits

    by Felipe M. Berg, Eric C. Abenojar, Pinunta Nittayacharn, Nathan K. Hoggard, Sidhartha Tavri, Jing Wang, Felipe Matsunaga, Michaela B. Cooley, Dana Wegierak, Xinning Wang, et al.

    The localization of prostate cancer by ultrasound remains limited by the lack of B-mode conspicuity and the confinement of clinically approved microbubbles (MBs) to the vasculature. This precludes the differentiation of viable tumor tissue, necrotic tissue, and margin-associated disease. We investigate the use of prostate-specific membrane antigen (PSMA)-targeted lipid-shelled perfluorocarbon nanobubbles (PSMA-NBs) in an orthotopic rabbit model using a clinical CEUS system. We implanted PSMA-positive PC3pip-GFP tumors into the prostates of immunosuppressed New Zealand White rabbits and performed transabdominal imaging with PSMA-NBs, MBs, and untargeted nanobubbles (Plain-NB) using the same imaging and analysis protocols. To address tumor heterogeneity and ultrasound boundary ambiguity, ROIs were defined from baseline B-mode images and segmented into the tumor core, rim, and a surrounding peritumoral area. Pixel-wise parametric and decorrelation time (DT) maps were generated and correlated with whole-slide histology (H&E) and PSMA IHC. Compared to MBs, PSMA-NBs exhibited higher peak intensities in the tumor core and rim (1.60-fold and 1.50-fold, respectively) and improved retention (mean transit time: 4.20 to 4.50-fold higher) for up to 10 minutes in the tumor and peritumoral areas. PSMA-NB kinetic and DT parameters also correlated with histology-defined tumor viability and PSMA expression. Compared to Plain-NBs, PSMA-NBs also exhibited improved retention (MTT +21%; AUCwo) in the rim and peritumoral areas. This study demonstrates the capability of PSMA-NBs to characterize prostate cancer by molecular CEUS beyond what is possible with conventional MBs.


  • Open Access

    Foam Fortification: Effect of Perfluorocarbon Gases on the Stability of Sclerosing Agent Foams

    by Henry Ruhl, Felipe M. Berg, Amir A. Rahnemai-Azar, Salim Abboud, Agata A. Exner


  • Open Access

    Nanobubble Contrast Enhanced Ultrasound Imaging: A Review

    by Dana Wegierak, Pinunta Nittayacharn, Michaela B. Cooley, Felipe M. Berg, Theresa Kosmides, Dorian Durig, Michael C. Kolios, Agata A. Exner

    Contrast‐enhanced ultrasound is currently used worldwide with clinical indications in cardiology and radiology, and it continues to evolve and develop through innovative technological advancements. Clinically utilized contrast agents for ultrasound consist of hydrophobic gas microbubbles stabilized with a biocompatible shell. These agents are used commonly in echocardiography, with emerging applications in cancer diagnosis and therapy. Microbubbles are a blood pool agent with diameters between 1 and 10 μm, which precludes their use in other extravascular applications. To expand the potential use of contrast‐enhanced ultrasound beyond intravascular applications, sub‐micron agents, often called nanobubbles or ultra‐fine bubbles, have recently emerged as a promising tool. Combining the principles of ultrasound imaging with the unique properties of nanobubbles (high concentration and small size), recent work has established their imaging potential. Contrast‐enhanced ultrasound imaging using these agents continues to gain traction, with new studies establishing novel imaging applications. We highlight the recent achievements in nonlinear nanobubble contrast imaging, including a discussion on nanobubble formulations and their acoustic characteristics. Ultrasound imaging with nanobubbles is still in its early stages, but it has shown great potential in preclinical research and animal studies. We highlight unexplored areas of research where the capabilities of nanobubbles may offer new advantages. As technology advances, this technique may find applications in various areas of medicine, including cancer detection and treatment, cardiovascular imaging, and drug delivery.


  • Open Access

    Ultrasound-mediated drug-free theranostics for treatment of prostate cancer

    by Reshani Himashika Perera, Felipe Matias Berg, Eric Chua Abenojar, Pinunta Nittayacharn, Youjoung Kim, Xinning Wang, James Peter Basilion, Agata Exner

    Lipid-shelled nanobubbles (NBs) can be visualized and activated using noninvasive ultrasound (US) stimulation, leading to significant bioeffects. Prior work demonstrates that active targeting of NBs to prostate-specific membrane antigen (PSMA) overexpressed in prostate cancer (PCa) results in enhanced cellular internalization and prolongs NB retention with persistent, cancer-cell specific acoustic activity. In this work, we hypothesized that tumor-accumulated PSMA-NBs combined with low frequency unfocused therapeutic US (TUS) will lead to selective damage and induce a specific therapeutic effect in PSMA-expressing tumors compared to PSMA-negative tumors. We observed that the internalized NBs and cellular compartments were disrupted after the PSMA-NB + TUS (targeted NB therapy or TNT) application, yet treated cells remained intact and viable. In vivo, PSMA-expressing tumors in mice receiving TNT treatment demonstrated a significantly greater extent of apoptosis (78.4 ± 9.3 %, p < 0.01) compared to controls. TNT treatment significantly inhibited the PSMA expressing tumor growth and increased median survival time by 103 %, p < 0.001). A significant reduction in tumor progression compared to untreated control was also seen in an orthotopic rabbit PCa model. Results demonstrate that cavitation of PSMA-NBs internalized via receptor-mediated endocytosis into target PCa cells using unfocused ultrasound results in significant, tumor-specific bioeffects. The effects, while not lethal to PSMA-expressing cancer cells in vitro, result in significant in vivo reduction in tumor progression in two models of PCa. While the mechanism of action of these effects is yet unclear, it is likely related to a locally-induced immune response, opening the door to future investigations in this area.


  • Open Access

    Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease

    by Felipe M. Berg, Eduardo T. O. Correia, Eric C. Abenojar, James P. Basilion, Thomas J. Rosol, Ronaldo H. Baroni, Agata A. Exner, Leonardo K. Bittencourt

    Background: There is an increasing interest in using preclinical models for development and assessment of medical devices and imaging techniques for prostatic disease care. Still, a comprehensive assessment of the prostate's radiological anatomy in primary preclinical models such as dogs, rabbits, and mice utilizing human anatomy as a reference point remains necessary with no optimal model for each purpose being clearly defined in the literature. Therefore, this study compares the anatomical characteristics of different animal models to the human prostatic gland from the imaging perspective.Methods: We imaged five Beagle laboratory dogs, five New Zealand White rabbits, and five mice, all sexually mature males, under Institutional Animal Care and Use Committee (IACUC) approval. Ultrasonography (US) was performed using the Vevo® F2 for mice (57 MHz probe). Rabbits and dogs were imaged using the Siemens® Acuson S3000 (17 MHz probe) and endocavitary (8 MHz) probes, respectively. Magnetic resonance imaging (MRI) was also conducted with a 7T scanner in mice and 3T scanner in rabbits and dogs.Results: Canine transrectal US emerged as the optimal method for US imaging, depicting a morphologically similar gland to humans but lacking echoic zonal differentiation. MRI findings in canines indicated a homogeneously structured gland similar to the human peripheral zone on T2‐weighted images (T2W) and apparent diffusion coefficient (ADC). In rabbits, US imaging faced challenges due to the pubic symphysis, whereas MRI effectively visualized all structures with the prostate presenting a similar aspect to the human peripheral gland on T2W and ADC maps. Murine prostate assessment revealed poor visualization of the prostate glands in ultrasound due to its small size, while 7T MRI delineated the distinct prostates and its lobes, with the lateral and dorsal prostate resembling the peripheral zone and the anterior prostate the central zone of the human gland.Conclusion: Dogs stand out as superior models for advanced preclinical studies in prostatic disease research. However, mice present as a good model for early stage studies and rabbits are a cost‐effective alternative and serve as valuable tools in specific research domains when canine research is not feasible.


  • Open Access

    Assessing Tumor Microenvironment Characteristics and Stratifying EPR with a Nanobubble Companion Nanoparticle via Contrast-Enhanced Ultrasound Imaging

    by Michaela B. Cooley, Dana Wegierak, Reshani Perera, Eric C. Abenojar, Pinunta A. Nittayacharn, Felipe M. Berg, Youjoung Kim, Michael C. Kolios, Agata A. Exner

    The tumor microenvironment is characterized by dysfunctional endothelial cells, resulting in heightened vascular permeability. Many nanoparticle-based drug delivery systems attempt to use this enhanced permeability combined with impaired lymphatic drainage (a concept known as the ‘enhanced permeability and retention effect’ or EPR effect) as the primary strategy for drug delivery, but this has not proven to be as clinically effective as anticipated. The specific mechanisms behind the inconsistent clinical outcomes of nanotherapeutics have not been clearly articulated, and the field has been hampered by a lack of accessible tools to study EPR-associated phenomena in clinically relevant scenarios. While medical imaging has tremendous potential to contribute to this area, it has not been broadly explored. This work examines, for the first time, the use of multiparametric dynamic contrast-enhanced ultrasound (CEUS) with a novel nanoscale contrast agent to examine tumor microenvironment characteristics noninvasively and in real-time. We demonstrate that CEUS imaging can: (1) evaluate tumor microenvironment features and (2) be used to help predict the distribution of doxorubicin-loaded liposomes in the tumor parenchyma. CEUS using nanobubbles (NBs) was carried out in two tumor types of high (LS174T) and low (U87) vascular permeability, and time-intensity curve (TIC) parameters were evaluated in both models prior to injection of doxorubicin liposomes. Consistently, LS174T tumors showed significantly different TIC parameters, including area under the rising curve (2.7x), time to peak intensity (1.9x) and decorrelation time (DT, 1.9x) compared to U87 tumors. Importantly, the DT parameter successfully predicted tumoral nanoparticle distribution (r = 0.86 ± 0.13). Ultimately, substantial differences in NB-CEUS generated parameters between LS174T and U87 tumors suggest that this method may be useful in determining tumor vascular permeability and could be used as a biomarker for identifying tumor characteristics and predicting sensitivity to nanoparticle-based therapies. These findings could ultimately be applied to predicting treatment efficacy and to evaluating EPR in other diseases with pathologically permeable vasculature.